Hal Barron, GlaxoSmithKline R&D chief (GSK via YouTube)
GlaxoSmithKline scraps two key mid-stage trials for their ICOS drug in the latest setback for the field
Another ICOS cancer drug program is running into stormy weather, with more bad news for GlaxoSmithKline R&D chief Hal Barron.
GSK put out word on …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.